Literature DB >> 16022169

An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.

Patrick J Kelly1, Nigel Stallard, Susan Todd.   

Abstract

There is increasing interest in combining Phases II and III of clinical development into a single trial in which one of a small number of competing experimental treatments is ultimately selected and where a valid comparison is made between this treatment and the control treatment. Such a trial usually proceeds in stages, with the least promising experimental treatments dropped as soon as possible. In this paper we present a highly flexible design that uses adaptive group sequential methodology to monitor an order statistic. By using this approach, it is possible to design a trial which can have any number of stages, begins with any number of experimental treatments, and permits any number of these to continue at any stage. The test statistic used is based upon efficient scores, so the method can be easily applied to binary, ordinal, failure time, or normally distributed outcomes. The method is illustrated with an example, and simulations are conducted to investigate its type I error rate and power under a range of scenarios.

Mesh:

Year:  2005        PMID: 16022169     DOI: 10.1081/BIP-200062857

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  12 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Longitudinal clinical trials with adaptive choice of follow-up time.

Authors:  Neal Jeffries; Nancy L Geller
Journal:  Biometrics       Date:  2015-03-27       Impact factor: 2.571

3.  Discussion on "A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials" by Elena M. Buzaianu and Pinyuen Chen.

Authors:  Peter F Thall
Journal:  Seq Anal       Date:  2009-01-01       Impact factor: 0.927

4.  A novel evaluation of optimality for randomized controlled trials.

Authors:  Jo Wick; Scott M Berry; Hung-Wen Yeh; Won Choi; Christina M Pacheco; Christine Daley; Byron J Gajewski
Journal:  J Biopharm Stat       Date:  2016-06-13       Impact factor: 1.051

5.  Adaptive design clinical trials: Methodology, challenges and prospect.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

6.  Adaptive designs for subpopulation analysis optimizing utility functions.

Authors:  Alexandra C Graf; Martin Posch; Franz Koenig
Journal:  Biom J       Date:  2014-11-14       Impact factor: 2.207

7.  Optimizing the data combination rule for seamless phase II/III clinical trials.

Authors:  Lisa V Hampson; Christopher Jennison
Journal:  Stat Med       Date:  2014-10-15       Impact factor: 2.373

Review 8.  Adaptive design methods in clinical trials - a review.

Authors:  Shein-Chung Chow; Mark Chang
Journal:  Orphanet J Rare Dis       Date:  2008-05-02       Impact factor: 4.123

9.  A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.

Authors:  Cornelia Ursula Kunz; Tim Friede; Nicholas Parsons; Susan Todd; Nigel Stallard
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

10.  Some recommendations for multi-arm multi-stage trials.

Authors:  James Wason; Dominic Magirr; Martin Law; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2012-12-12       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.